Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eye disorder therapy- Re-Vana Therapeutics

Next Previous
X
Search
Drug Profile

Eye disorder therapy- Re-Vana Therapeutics

Alternative Names: EyeLief and OcuLief® - Re-Vana Therapeutics

Latest Information Update: 30 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Re-Vana Therapeutics
  • Developer Re-Vana Therapeutics; Unknown
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Eye disorders

Most Recent Events

  • 30 Aug 2024 Re-Vana Therapeutics has patent protection for EyeLief® and OcuLief® implants, prior to August 2024 (Re-Vana Therapeutics pipeline, August 2024)
  • 13 Aug 2024 Early research in Eye disorders in United Kingdom (Injection), prior to August 2024 (Re-Vana Therapeutics pipeline, August 2024)
  • 13 Aug 2024 Early research in Eye disorders in United Kingdom (Intraocular), prior to August 2024 (Re-Vana Therapeutics pipeline, August 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top